美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Apimeds Pharmaceutical U.S, Inc.

1.64

-0.4500-21.53%

盤後：1.63-0.0100-0.61%19:30 EDT

成交量：6.63萬

成交額：12.53萬

市值：247.50萬

市盈率：-0.04

高：2.11

開：2.11

低：1.60

收：2.09

52周最高：59.70

52周最低：1.60

股本：150.91萬

流通股本：30.47萬

量比：2.39

換手率：21.76%

股息：- -

股息率：- -

每股收益(TTM):-38.5450

每股收益(LYR):-0.1759

淨資產收益率：-144.99%

總資產收益率：-69.29%

市淨率：0.30

市盈率(LYR):-9.33

資料載入中...

總覽公司新聞資訊公告

Apimeds Pharmaceuticals US董事會過渡期調整：僅保留四名成員——SEC文件披露

Apimeds Pharmaceuticals US於2026年9月10日簽署和解協議第一修正案——SEC文件披露

SEC文件揭示：Freet已將全部Apitox相關權利轉讓予Apimeds Pharmaceuticals

Apimeds Pharmaceuticals US獲Apitox韓國診所獨家權利、美國25%特許權使用費及海外25%收入分成——SEC文件披露

Apimeds製藥美國公司依據和解協議，將在七個工作日內設立全新全資子公司

Apimeds Pharmaceuticals US與Inscobee達成和解；合併進程繼續，1億美元PIPE融資即將完成，LŌKahi Therapeutics將推進Apitox項目

Apimeds Pharmaceuticals US Inc任命蔡成俊為聯席首席執行官 2026年5月4日生效 - 美國證券交易委員會備案文件

Apimeds製藥美國公司 - Lokahi保留Apitox項目全部權利含220萬美元Prevail CRO信貸額度 - 美國證監會文件

Apimeds製藥美國公司與Inscobee達成和解協議

Apimeds Pharmaceuticals美國公司不承認與股東同意書相關的趙英植董事任命

Apimeds Pharmaceuticals US Inc：Vin Menon 連任公司首席執行官

Apimeds Pharmaceuticals（非「Apimeds Korea」）任命趙英植為董事會主席 - 美國證券交易委員會文件

Apimeds製藥公司3月20日公告：即刻解除Elona Kogan等四位董事職務

Apimeds Pharmaceuticals US Inc 任命趙先生為首席執行官、餘先生為秘書，即時生效——美國證券交易委員會文件披露

Apimeds Pharmaceuticals US Inc. 宣佈Inscobee Inc. (Ks:006490)及Apimeds Inc.存在重大違約行為擬向特拉華州衡平法院提起緊急訴訟

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/APUS/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"APUS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APUS\",,,,,undefined,":{"symbol":"APUS","market":"US","secType":"STK","nameCN":"Apimeds Pharmaceutical  U.S, Inc.","latestPrice":1.64,"timestamp":1789502400000,"preClose":2.09,"halted":0,"volume":66300,"hourTrading":{"tag":"盘后","latestPrice":1.63,"preClose":1.64,"latestTime":"19:30 EDT","volume":951,"amount":1555.0082,"timestamp":1789515005275,"change":-0.01,"changeRate":-0.006098,"amplitude":0.009878},"delay":0,"changeRate":-0.21531100478468898,"floatShares":304730,"shares":1509119,"eps":-38.545,"marketStatus":"已收盤","change":-0.45,"latestTime":"09-15 16:00:00 EDT","open":2.11,"high":2.1101,"low":1.6,"amount":125311.03104,"amplitude":0.244067,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-38.545,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":5,"adr":0,"listingDate":1746763200000,"exchange":"AMEX","adjPreClose":2.09,"preHourTrading":{"tag":"盘前","latestPrice":2.1574,"preClose":2.09,"latestTime":"08:26 EDT","volume":2419,"amount":4979.1401835,"timestamp":1789475189793,"change":0.0674,"changeRate":0.032249,"amplitude":0.118325},"postHourTrading":{"tag":"盘后","latestPrice":1.63,"preClose":1.64,"latestTime":"19:30 EDT","volume":951,"amount":1555.0082,"timestamp":1789515005275,"change":-0.01,"changeRate":-0.006098,"amplitude":0.009878},"volumeRatio":2.390705},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APUS\",,,,,undefined,":{"symbol":"APUS","floatShares":304730,"roa":"-69.29%","roe":"-144.99%","lyrEps":-0.175862,"volumeRatio":2.390705,"shares":1509119,"dividePrice":0,"high":2.1101,"amplitude":0.244067,"preClose":2.09,"low":1.6,"week52Low":1.6,"pbRate":"0.30","week52High":59.7,"institutionHeld":0,"latestPrice":1.64,"eps":-38.545,"divideRate":0,"volume":66300,"delay":0,"ttmEps":-38.545,"open":2.11,"prevYearClose":16.4,"prevWeekClose":2.105,"prevMonthClose":3.88,"prevQuarterClose":9,"fiveDayClose":2.3,"twentyDayClose":4.28,"sixtyDayClose":10.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APUS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-24","symbol":"APUS","defaultRemindTime":1784899800000,"type":"split","dateTimestamp":1784865600000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APUS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APUS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APUS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APUS","date":"2025-12-01","current":-0.042548,"percent":0.642384,"low":-37.866629,"twenty":-14.293061,"median":-12.284712,"eighty":-6.374893,"high":-4.754876,"avg":-11.953693,"sd":7.073766,"marketCap":36470350},"quantilePoints":[{"date":"2025-02-21","current":-34.716764,"twenty":-34.716764,"median":-34.716764,"eighty":-34.716764,"marketCap":57120291},{"date":"2025-02-28","current":-34.716764,"twenty":-34.716764,"median":-34.716764,"eighty":-34.716764,"marketCap":57120291},{"date":"2025-03-05","current":-34.716764,"twenty":-34.716764,"median":-34.716764,"eighty":-34.716764,"marketCap":57120291},{"date":"2025-05-09","current":-18.309826,"twenty":-34.716764,"median":-34.716764,"eighty":-33.299512,"marketCap":25450475},{"date":"2025-05-16","current":-14.148502,"twenty":-34.716764,"median":-34.008138,"eighty":-15.063993,"marketCap":19666276},{"date":"2025-05-23","current":-14.074662,"twenty":-34.716764,"median":-18.309826,"eighty":-14.306662,"marketCap":21054484},{"date":"2025-05-30","current":-13.387434,"twenty":-34.716764,"median":-15.063993,"eighty":-14.061031,"marketCap":20026450},{"date":"2025-06-06","current":-14.702962,"twenty":-34.716764,"median":-14.800251,"eighty":-13.996937,"marketCap":21994367},{"date":"2025-06-13","current":-14.314495,"twenty":-34.716764,"median":-14.564634,"eighty":-14.061031,"marketCap":21413253},{"date":"2025-06-20","current":-13.774354,"twenty":-33.866413,"median":-14.548195,"eighty":-14.0474,"marketCap":20605249},{"date":"2025-06-27","current":-13.296895,"twenty":-33.299512,"median":-14.356338,"eighty":-13.867215,"marketCap":19891011},{"date":"2025-07-03","current":-13.774354,"twenty":-27.303638,"median":-14.27266,"eighty":-13.727614,"marketCap":20605249},{"date":"2025-07-11","current":-14.006506,"twenty":-17.177946,"median":-14.161274,"eighty":-13.727614,"marketCap":20952529},{"date":"2025-07-18","current":-13.851738,"twenty":-15.354982,"median":-14.154888,"eighty":-13.727614,"marketCap":20721009},{"date":"2025-07-25","current":-16.173259,"twenty":-16.219689,"median":-14.161274,"eighty":-13.727614,"marketCap":24193804},{"date":"2025-08-01","current":-13.464818,"twenty":-16.219689,"median":-14.199966,"eighty":-13.727614,"marketCap":20142210},{"date":"2025-08-08","current":-12.14929,"twenty":-16.049445,"median":-14.148502,"eighty":-13.573156,"marketCap":18174293},{"date":"2025-08-15","current":-12.265366,"twenty":-15.710284,"median":-14.056061,"eighty":-13.418388,"marketCap":18347933},{"date":"2025-08-22","current":-7.697345,"twenty":-15.447843,"median":-14.006506,"eighty":-13.015991,"marketCap":28547481},{"date":"2025-08-29","current":-6.307075,"twenty":-15.306558,"median":-13.929122,"eighty":-12.721932,"marketCap":23391328},{"date":"2025-09-05","current":-6.307075,"twenty":-15.146611,"median":-13.929122,"eighty":-12.474303,"marketCap":23391328},{"date":"2025-09-12","current":-6.578348,"twenty":-15.038217,"median":-13.851738,"eighty":-12.234412,"marketCap":24397407},{"date":"2025-09-19","current":-6.205348,"twenty":-14.9276,"median":-13.774354,"eighty":-7.507455,"marketCap":23014048},{"date":"2025-09-26","current":-6.049367,"twenty":-14.889578,"median":-13.773581,"eighty":-6.849619,"marketCap":22435553},{"date":"2025-10-03","current":-5.832349,"twenty":-14.826776,"median":-13.69697,"eighty":-6.578348,"marketCap":21630690},{"date":"2025-10-10","current":-6.307075,"twenty":-14.675296,"median":-13.542202,"eighty":-6.472551,"marketCap":23391328},{"date":"2025-10-17","current":-6.239257,"twenty":-14.561346,"median":-13.50351,"eighty":-6.415584,"marketCap":23139808},{"date":"2025-10-24","current":-5.879822,"twenty":-14.548195,"median":-13.387434,"eighty":-6.358617,"marketCap":21806754},{"date":"2025-10-31","current":-6.917438,"twenty":-14.538909,"median":-13.039206,"eighty":-6.374893,"marketCap":25655005},{"date":"2025-11-07","current":-8.524725,"twenty":-14.481047,"median":-12.845746,"eighty":-6.381675,"marketCap":31616021},{"date":"2025-11-14","current":-9.460613,"twenty":-14.381444,"median":-12.652286,"eighty":-6.415584,"marketCap":35086992},{"date":"2025-11-21","current":-5.852155,"twenty":-14.312928,"median":-12.458826,"eighty":-6.415584,"marketCap":30182359},{"date":"2025-11-28","current":-7.071353,"twenty":-14.306662,"median":-12.304058,"eighty":-6.374893,"marketCap":36470350},{"date":"2025-12-01","current":-7.071353,"twenty":-14.293061,"median":-12.284712,"eighty":-6.374893,"marketCap":36470350}],"updateTime":1789526320826},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APUS\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1121862226","title":"Apimeds Pharmaceuticals US董事會過渡期調整：僅保留四名成員——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1121862226","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121862226?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 21:13","pubTimestamp":1789132390,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新提交的文件，Apimeds Pharmaceuticals US公司透露，在过渡期内其董事会成员将缩减至仅四名。市场观察人士或将对此举动的潜在意图及其对公司决策流程的影响保持关注。外界普遍推测，此举或在为更广泛的治理改革铺路，不过截至目前，官方未就成员缩减的具体原因或预计过渡期时长给出明确说明。随着更多细节浮出水面，投资者与行业分析者预计将密切关注这一发展动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157325852","title":"Apimeds Pharmaceuticals US於2026年9月10日簽署和解協議第一修正案——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1157325852","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157325852?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 21:12","pubTimestamp":1789132331,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US——这家制药公司于2026年9月10日签署了和解协议的第一修正案。相关细节已通过美国证券交易委员会（SEC）的文件正式对外披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142452397","title":"SEC文件揭示：Freet已將全部Apitox相關權利轉讓予Apimeds Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=1142452397","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142452397?lang=zh_tw&edition=fundamental","pubTime":"2026-08-22 05:14","pubTimestamp":1787346850,"startTime":"0","endTime":"0","summary":"一项最新提交至美国证券交易委员会的文件显示，Apimeds Pharmaceuticals US已获得Freet方面转让的全部Apitox相关权益。这一动作意味着，围绕Apitox的所有权归属问题，如今已有了明确的界定与交接。根据该文件内容，Freet将其与Apitox相关的所有权利完整地转移给了Apimeds Pharmaceuticals。此举或将对Apimeds Pharmaceuticals未来的业务布局与产品管线产生深远影响。随着权利的正式移交，Apimeds Pharmaceuticals US如今握有更为集中的资源，未来其如何利用这一优势，值得持续关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111642266","title":"Apimeds Pharmaceuticals US獲Apitox韓國診所獨家權利、美國25%特許權使用費及海外25%收入分成——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1111642266","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111642266?lang=zh_tw&edition=fundamental","pubTime":"2026-08-22 05:14","pubTimestamp":1787346850,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新披露的文件，Apimeds Pharmaceuticals US已就其核心产品Apitox达成一项重要协议。该公司获得了该产品在韩国诊所领域的100%独家权利，同时在美国市场享有25%的特许权使用费，并可参与海外市场25%的收入分成。协议条款清晰界定了各区域市场的利益分配机制——韩国市场侧重权利掌控，美国及海外市场则通过收益共享模式实现多方共赢。文件内容显示，此次权利与收益分配方案已正式确立，为Apitox的全球市场推广奠定了明确的商业框架。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170470171","title":"Apimeds製藥美國公司依據和解協議，將在七個工作日內設立全新全資子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1170470171","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170470171?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 02:09","pubTimestamp":1778004553,"startTime":"0","endTime":"0","summary":"根据最新达成的和解协议条款，Apimeds制药美国公司已承诺在七个工作日的期限内完成全新全资子公司的组建工作。这一举措标志着公司在战略重组方面迈出关键一步，旨在优化业务架构并提升运营效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111825147","title":"Apimeds Pharmaceuticals US與Inscobee達成和解；合併進程繼續，1億美元PIPE融資即將完成，LŌKahi Therapeutics將推進Apitox項目","url":"https://stock-news.laohu8.com/highlight/detail?id=1111825147","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111825147?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 02:07","pubTimestamp":1778004434,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceutical U.S, Inc.已与Inscobee达成和解协议，公司合并计划将按原定方案继续推进。与此同时，一项高达1亿美元的PIPE融资也即将完成交割。\n作为合并后实体的一部分，LŌKahi Therapeutics将获得资金支持，重点推进其Apitox项目的研发进程。这一系列进展标志着公司在战略布局和资本运作方面取得重要突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163822956","title":"Apimeds Pharmaceuticals US Inc任命蔡成俊為聯席首席執行官 2026年5月4日生效 - 美國證券交易委員會備案文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1163822956","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163822956?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 00:32","pubTimestamp":1777998734,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新备案文件披露，Apimeds Pharmaceuticals US Inc（股票代码：APUS）已正式任命蔡成俊（Sungjoon Chae）担任公司联席首席执行官。此项高管人事变动将于2026年5月4日正式生效。\n此次任命标志着该公司在战略领导层配置上的重要调整。蔡成俊将与其他高管团队协同工作，共同推动公司的业务发展和战略规划实施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190941409","title":"Apimeds製藥美國公司 - Lokahi保留Apitox項目全部權利 含220萬美元Prevail CRO信貸額度 - 美國證監會文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1190941409","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190941409?lang=zh_tw&edition=fundamental","pubTime":"2026-05-04 18:20","pubTimestamp":1777890015,"startTime":"0","endTime":"0","summary":"根据美国证监会最新披露文件，Apimeds制药美国公司（APUS）宣布其合作伙伴Lokahi已全面保留对Apitox项目的所有权利。此项权利保留协议涵盖价值220万美元的Prevail合同研究组织信贷额度，标志着该项目资产关系的正式确认。\n该安排确保了Lokahi对Apitox研发计划的完整控制权，同时维持了与Prevail CRO的金融合作框架。此次权利确认将为Apitox项目的后续临床开发提供稳定的资金支持与法律保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158149099","title":"Apimeds製藥美國公司與Inscobee達成和解協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1158149099","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158149099?lang=zh_tw&edition=fundamental","pubTime":"2026-05-04 18:19","pubTimestamp":1777889954,"startTime":"0","endTime":"0","summary":"根据2026年4月24日提交给美国证券交易委员会的文件显示，Apimeds制药美国公司已与Inscobee正式签署和解协议。该协议的达成标志着双方长期争议的终结，为企业未来的稳定发展奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145648350","title":"Apimeds Pharmaceuticals美國公司不承認與股東同意書相關的趙英植董事任命","url":"https://stock-news.laohu8.com/highlight/detail?id=1145648350","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145648350?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 04:52","pubTimestamp":1774558332,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceutical U.S, Inc. 宣布，公司不认可通过股东同意书程序单方面推选的赵英植（Youngjik Cho）担任董事的任命。该任命程序未遵循公司章程规定的正式流程，公司管理层认为此次人事变动缺乏法律效力。董事会将依法采取必要措施维护公司治理结构的稳定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108096192","title":"Apimeds Pharmaceuticals US Inc：Vin Menon 連任公司首席執行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1108096192","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108096192?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 04:50","pubTimestamp":1774558251,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US Inc 宣布，Vin Menon 将继续担任公司首席执行官一职。这一决定彰显了董事会对其领导能力的持续信任。作为公司战略的核心推动者，Menon 将带领团队进一步拓展医药研发与市场布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115852730","title":"Apimeds Pharmaceuticals（非「Apimeds Korea」）任命趙英植為董事會主席 - 美國證券交易委員會文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1115852730","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115852730?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:22","pubTimestamp":1774437721,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals（非“Apimeds Korea”）宣布任命赵英植（Youngjik Cho）为公司董事会主席，此项人事变动已通过美国证券交易委员会（SEC）文件正式披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149182711","title":"Apimeds製藥公司3月20日公告：即刻解除Elona Kogan等四位董事職務","url":"https://stock-news.laohu8.com/highlight/detail?id=1149182711","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149182711?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:09","pubTimestamp":1774436997,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新披露的文件，Apimeds制药公司于3月20日宣布，立即解除Elona Kogan、Jakap Koo、Carol O'Donnell及Bennett Weintraub四人的董事职务。这一重大人事变动即刻生效，标志着公司治理结构迎来重要调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111374503","title":"Apimeds Pharmaceuticals US Inc 任命趙先生為首席執行官、餘先生為秘書，即時生效——美國證券交易委員會文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1111374503","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111374503?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:09","pubTimestamp":1774436960,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新文件披露，Apimeds Pharmaceuticals US Inc已正式宣布两项关键人事任命：赵先生出任公司首席执行官，余先生担任公司秘书。两项任命均自公告之日起立即生效。此次高层变动标志着APUS在战略执行和公司治理方面迈出重要一步。新任CEO赵先生将全面负责公司的整体运营及业务发展方向，而余先生作为秘书，将协助强化公司合规管理与信息披露事务。市场关注此次人事调整是否将为Apimeds Pharmaceuticals US Inc带来新的发展策略或业务重组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191294940","title":"Apimeds Pharmaceuticals US Inc. 宣佈Inscobee Inc. (Ks:006490)及Apimeds Inc.存在重大違約行為 擬向特拉華州衡平法院提起緊急訴訟","url":"https://stock-news.laohu8.com/highlight/detail?id=1191294940","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191294940?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 20:32","pubTimestamp":1774355549,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US Inc. 今日宣布，其已确认Inscobee Inc. (Ks:006490) 与Apimeds Inc. 严重违反了双方此前达成的合并协议条款。鉴于此重大违约行为，该公司正在准备相关法律文件，计划向特拉华州衡平法院提起紧急诉讼，以维护其合法权益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}